Why weight-loss drugs don’t work for some people

Why weight-loss drugs don’t work for some people

Understanding the limits of GLP-1 drugs

Over the past few years, GLP-1 receptor agonists such as semaglutide and tirzepatide have reshaped the medical approach to obesity. These medications, originally developed for type 2 diabetes, can produce an average weight loss of 15 to 20 percent of body weight in clinical trials. Yet a recent article from The Conversation draws attention to a persistent clinical puzzle: a notable subset of patients experiences minimal or no weight loss despite using these drugs as prescribed.

The piece underscores a reality that clinicians have observed since the first GLP-1 drugs entered the obesity market. While the group average is impressive, individual responses vary widely. Some patients lose less than 5 percent of their starting weight, a threshold often considered a minimal response. Others may lose weight initially only to plateau early. Understanding why this happens is not merely an academic question. It has direct implications for treatment decisions, patient expectations, and the future design of obesity therapies.

The Conversation article identifies several broad categories that help explain this variability: biological and genetic factors, lifestyle and adherence challenges, and the need for more refined research into individual patient profiles. Each category deserves a closer look.

Biological and genetic factors

At the heart of the variability lies the biology of the GLP-1 system itself. GLP-1 receptor agonists work by mimicking the natural hormone glucagon-like peptide-1, which is released from the gut after eating. This hormone binds to receptors in the pancreas to stimulate insulin secretion and suppress glucagon release. It also acts on the brain to reduce appetite and slows gastric emptying so that food stays in the stomach longer, promoting fullness.

But not every individual’s body handles this mimic equally. The Conversation article points to differences in individual biology as a key factor, noting that genetic variations can affect how the body responds to these drugs. For example, single nucleotide polymorphisms in the GLP-1 receptor gene have been linked to altered receptor sensitivity. People carrying certain variants may have a lower affinity for the drug, reducing its ability to suppress hunger or delay gastric emptying.

Beyond genetics, there are other biological mechanisms at play. The gut microbiome, which differs substantially from person to person, can influence how GLP-1 drugs are metabolized and how much endogenous GLP-1 a person produces. Some individuals may also have a higher baseline level of compensatory appetite signals, such as ghrelin or neuropeptide Y, that counteract the drug’s effects. The Conversation article mentions that some people may have a lower sensitivity to the drug’s effects, a statement supported by pharmacological data showing that the dose-response curve for weight loss is not uniform across populations.

Hormonal factors related to insulin resistance and thyroid function can further modulate the drug’s efficacy. For instance, patients with severe insulin resistance may require higher doses or longer treatment durations to see meaningful changes. The article correctly emphasizes that the current state of knowledge does not yet allow clinicians to predict with confidence who will be a non-responder.

Lifestyle and adherence challenges

The Conversation article also highlights that lifestyle factors play a role in determining outcomes. This is not simply a matter of willpower. The drugs are most effective when combined with dietary changes and physical activity, a point that is reinforced by the prescribing guidelines for every GLP-1 agonist approved for weight management.

Patients who do not modify their eating habits may see less benefit, partly because the drug cannot compensate for a diet that is extremely high in calories or rich in heavily processed foods. The pharmacology of GLP-1 receptor agonists involves a reduction in appetite and an increase in satiety, but the drug does not erase cravings or change learned eating behaviors overnight. Without conscious effort to adopt a lower-calorie, nutrient-dense diet, the drug’s effect can be blunted.

Adherence to the medication schedule is another critical variable. GLP-1 drugs are typically injected weekly, but many patients miss doses due to injection site reactions, nausea, or simple forgetfulness. In real-world studies, adherence rates to GLP-1 medications for obesity are significantly lower than in tightly controlled clinical trials. The Conversation article notes that patients who struggle with adherence to the medication schedule may see less benefit.

Moreover, side effects such as nausea, vomiting, and diarrhea can lead some patients to discontinue therapy or reduce their dose voluntarily. Gastrointestinal tolerability is one of the most common reasons for early dropout from GLP-1 treatment. The article’s emphasis on the drugs not being a standalone solution but part of a broader weight management strategy is a crucial reminder. No medication works in isolation; the behavioral context matters.

Individual response and future research

The Conversation article concludes that more research is needed to understand why some patients do not respond. It suggests that identifying biomarkers or genetic profiles could help predict which individuals will benefit most from GLP-1 drugs. This is an area of active investigation.

Several research groups are now conducting genome-wide association studies to find loci associated with GLP-1 treatment response. Early data suggest that polymorphisms in genes related to the melanocortin system, which regulates energy balance, may also play a role. Other researchers are examining the role of bile acid metabolism and its interaction with GLP-1 signaling. The article emphasizes that the current understanding of these medications is still evolving, and patient variability remains an area of active investigation.

Methodologically, future trials will need to be designed with stratification based on baseline characteristics such as insulin sensitivity, gut microbiome composition, and genetic markers. The Conversation article rightly points out that such an approach could eventually allow clinicians to select the right drug for the right patient from the outset, rather than relying on trial and error.

Another emerging area is the use of combination therapies. Because obesity is a multifactorial disease, a single mechanism may not be sufficient for everyone. Drugs that combine GLP-1 receptor agonism with other hormonal targets, such as GIP or amylin, may improve response rates. Tirzepatide, which activates both GLP-1 and GIP receptors, has already shown higher average weight loss than semaglutide. And dual- and triple-agonist combinations are in development.

The Conversation article’s key message is that while GLP-1 drugs are a powerful tool, they are not a universal solution. Understanding the limits of these medications is as important as celebrating their successes. For the millions of people with obesity, knowing that a drug may not work for them is not a reason for despair but a call for more personalized approaches.

Frequently Asked Questions

Q: Are there alternative treatments for people who do not respond to GLP-1 drugs?

A: Yes. For individuals who experience minimal weight loss on a GLP-1 receptor agonist, physicians may consider switching to a different GLP-1 drug, trying a combination therapy such as tirzepatide, or exploring other classes of anti-obesity medications like phentermine-topiramate or bupropion-naltrexone. In some cases, bariatric surgery remains an option. Lifestyle interventions and counseling should always be part of the treatment plan regardless of medication choice.

Q: How common is non-response to GLP-1 weight-loss drugs?

A: In clinical trials of semaglutide for obesity, approximately 10 to 15 percent of participants achieved less than 5 percent weight loss, which is often considered a minimal response. Real-world data suggests the proportion may be higher, perhaps 20 to 30 percent, due to lower adherence and less stringent monitoring. Non-response is defined inconsistently across studies, so exact numbers vary.

Q: Can a person improve their response to GLP-1 drugs by changing their diet or exercise routine?

A: Yes. The Conversation article highlights that the drugs are most effective when combined with dietary changes and physical activity. Reducing calorie intake, increasing protein and fiber, and engaging in regular aerobic and resistance exercise can amplify the drug’s effect. Even small lifestyle modifications can turn a marginal response into a clinically meaningful one.

Q: Is there a way to test whether someone will respond to GLP-1 drugs before starting treatment?

A: Currently, there is no validated biomarker that can predict individual response to GLP-1 receptor agonists. Researchers are actively investigating genetic markers, gut microbiome profiles, and metabolic signatures that may one day guide treatment selection. Until then, the standard approach is to try a medication for 12 to 16 weeks and assess weight loss progress before deciding to continue, adjust, or change therapy.